Trial Profile

Clinical study of single arm and open label of Sintilimab combined with decitabine in the treatment of higher-risk myelodysplastic syndrome

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Decitabine (Primary) ; Sintilimab (Primary)
Indications Myelodysplastic syndromes
Focus Therapeutic Use

Most Recent Events

12 Dec 2023 Results (data cut-off on June 16, 2023, n=53 )assessing the safety and efficacy of sintilimab in combination with decitabine for patients with higher-risk MDS,presented at the 65th American Society of Hematology Annual Meeting and Exposition
01 Jul 2022 New trial record
17 Jun 2022 Preliminary Results (At data cut-off February 22, 2022; n= 21) presented at the 27th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com